RDHL vs. AVTX, PIRS, MNPR, KPRX, PPBT, HUGE, EDSA, IMNN, ELAB, and AKTX
Should you be buying RedHill Biopharma stock or one of its competitors? The main competitors of RedHill Biopharma include Avalo Therapeutics (AVTX), Pieris Pharmaceuticals (PIRS), Monopar Therapeutics (MNPR), Kiora Pharmaceuticals (KPRX), Purple Biotech (PPBT), FSD Pharma (HUGE), Edesa Biotech (EDSA), Imunon (IMNN), Elevai Labs (ELAB), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
Avalo Therapeutics (NASDAQ:AVTX) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.
RedHill Biopharma received 422 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 68.98% of users gave RedHill Biopharma an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
In the previous week, Avalo Therapeutics had 3 more articles in the media than RedHill Biopharma. MarketBeat recorded 4 mentions for Avalo Therapeutics and 1 mentions for RedHill Biopharma. Avalo Therapeutics' average media sentiment score of -0.68 beat RedHill Biopharma's score of -0.98 indicating that RedHill Biopharma is being referred to more favorably in the news media.
RedHill Biopharma has a net margin of 0.00% compared to RedHill Biopharma's net margin of -1,639.50%. Avalo Therapeutics' return on equity of 0.00% beat RedHill Biopharma's return on equity.
RedHill Biopharma has higher revenue and earnings than Avalo Therapeutics.
87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are held by institutional investors. 0.2% of Avalo Therapeutics shares are held by company insiders. Comparatively, 6.8% of RedHill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Avalo Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.47, suggesting that its share price is 247% more volatile than the S&P 500.
Summary
RedHill Biopharma beats Avalo Therapeutics on 10 of the 14 factors compared between the two stocks.
Get RedHill Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RedHill Biopharma Competitors List
Related Companies and Tools
